Certainly, its important for individuals considering these medications to be aware of these considerations and discuss them with their healthcare provider
For the majority of patients, the heart rate increase associated with GLP-1 receptor agonist therapy is not clinically significant and does not require treatment modification
Regular Follow-ups and Adjustments Follow-ups monitor side effects, adjust dosing, and decide when to pause, maintain, or taper
At The Institute for Weight Management, we view this first week as a retraining period
In RYBELSUS clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving RYBELSUS (7 mg 0.6%, 14 mg 2%) than placebo (0.3%)
Receive your weight loss treatment at your home